Results 91 to 100 of about 26,674 (238)

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon   +5 more
wiley   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen   +6 more
wiley   +1 more source

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? [PDF]

open access: yes, 2017
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA).
A Ferreiro-Iglesias   +140 more
core   +3 more sources

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

open access: yes, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick   +8 more
core   +1 more source

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

open access: yesArthritis Research & Therapy, 2019
Background To assess the risks of malignancies, infections and autoimmune diseases in patients with rheumatoid arthritis (RA) treated with abatacept compared with other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic
Gulsen Ozen   +4 more
doaj   +1 more source

Emerging immunopharmacological targets in multiple sclerosis. [PDF]

open access: yes, 2015
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the
Abdolmohamad Rostami   +182 more
core   +2 more sources

Fatal Chronic Varicella‐Zoster Viral Infection in a Young Man With Chediak–Higashi Syndrome

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Chediak–Higashi syndrome (CHS) is a rare autosomal recessive primary immunodeficiency characterized by partial oculocutaneous albinism, neurologic involvement, and a predisposition to severe infections. Patients are particularly susceptible to developing hemophagocytic lymphohistiocytosis (HLH), which significantly worsens prognosis. We report
Albane Badet   +4 more
wiley   +1 more source

Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19

open access: yesJAMA Network Open
Key Points Question Is abatacept exposure associated with clinical outcomes in patients with severe COVID-19? Findings In this secondary analysis of abatacept pharmacokinetics and exposure-response data for 395 hospitalized patients in the ACTIV-1 IM ...
Stephen J. Balevic   +318 more
semanticscholar   +1 more source

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production

open access: yesImmunological Medicine, 2020
Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-
Hisakata Yamada   +14 more
doaj   +1 more source

Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review

open access: yesPediatric Dermatology, EarlyView.
ABSTRACT Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb‐length discrepancies, and inflammatory arthropathy occurring more commonly in children.
Alexa Moschella   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy